ATE495255T1 - Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs - Google Patents

Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs

Info

Publication number
ATE495255T1
ATE495255T1 AT99942154T AT99942154T ATE495255T1 AT E495255 T1 ATE495255 T1 AT E495255T1 AT 99942154 T AT99942154 T AT 99942154T AT 99942154 T AT99942154 T AT 99942154T AT E495255 T1 ATE495255 T1 AT E495255T1
Authority
AT
Austria
Prior art keywords
scary
phenotype
gene
mouse
leads
Prior art date
Application number
AT99942154T
Other languages
English (en)
Inventor
Mary Brunkow
Eric Jeffery
Kathryn Hjerrild
Fred Ramsdell
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE495255T1 publication Critical patent/ATE495255T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99942154T 1998-08-11 1999-08-11 Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs ATE495255T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9619598P 1998-08-11 1998-08-11
PCT/US1999/018407 WO2000009693A2 (en) 1998-08-11 1999-08-11 Identification of the gene causing the mouse scurfy phenotype and its human ortholog

Publications (1)

Publication Number Publication Date
ATE495255T1 true ATE495255T1 (de) 2011-01-15

Family

ID=22256264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942154T ATE495255T1 (de) 1998-08-11 1999-08-11 Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs

Country Status (8)

Country Link
US (9) US6414129B1 (de)
EP (1) EP1105479B1 (de)
JP (4) JP4351807B2 (de)
AT (1) ATE495255T1 (de)
AU (1) AU5559499A (de)
CA (1) CA2339409A1 (de)
DE (1) DE69943129D1 (de)
WO (1) WO2000009693A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019026A1 (en) * 1995-06-05 2002-02-14 Daniel R. Soppet Human g-protein receptor hgber32
AU5559499A (en) * 1998-08-11 2000-03-06 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
AU2001285467A1 (en) * 2000-08-21 2002-03-04 Celltech R And D, Inc. Methods for detecting mutations in the human scurfy/foxp3 gene
CA2446112C (en) * 2001-05-08 2011-04-26 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
EP2064350B1 (de) * 2006-11-27 2013-01-02 Ludwig Institute for Cancer Research Ltd. Expression von foxp3 durch krebszellen
WO2008134524A2 (en) * 2007-04-25 2008-11-06 The Children's Hospital Of Philadelphia Compositions and methods for regulating t-cell activity
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
WO2012031031A2 (en) 2010-08-31 2012-03-08 Lawrence Ganeshalingam Method and systems for processing polymeric sequence data and related information
WO2012122555A2 (en) * 2011-03-09 2012-09-13 Lawrence Ganeshalingam Biological data networks and methods therefor
WO2013192631A1 (en) 2012-06-22 2013-12-27 Maltbie Dan System and method for secure, high-speed transfer of very large files
ES2665543B1 (es) 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos
WO2019202322A1 (en) 2018-04-18 2019-10-24 Ucl Business Plc Engineered regulatory t cell
WO2021163642A2 (en) * 2020-02-13 2021-08-19 The Board Of Trustees Of The Leland Stanford Junior University Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
AU6956698A (en) * 1997-04-10 1998-10-30 Genetics Institute Inc. Secreted expressed sequence tags (sests)
GB9721909D0 (en) 1997-10-17 1997-12-17 Cantab Pharma Res Gene delivery vectors and their uses
EP1025251A1 (de) 1997-10-21 2000-08-09 Targeted Genetics Corporation Vermehrbare 'verpackungs-kassetten' des adeno-assoziierten virus (aav) für die produktion von rekombinanten aav-vektoren
WO1999020773A2 (en) 1997-10-21 1999-04-29 Targeted Genetics Corporation TRANSCRIPTIONALLY-ACTIVATED AAV INVERTED TERMINAL REPEATS (ITRs) FOR USE WITH RECOMBINANT AAV VECTORS
AU5559499A (en) * 1998-08-11 2000-03-06 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
CA2446112C (en) * 2001-05-08 2011-04-26 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein

Also Published As

Publication number Publication date
WO2000009693A3 (en) 2000-06-15
US6683160B1 (en) 2004-01-27
JP2002538764A (ja) 2002-11-19
JP4351807B2 (ja) 2009-10-28
US6794145B1 (en) 2004-09-21
US6667162B1 (en) 2003-12-23
JP2010029204A (ja) 2010-02-12
US7220579B2 (en) 2007-05-22
AU5559499A (en) 2000-03-06
US6414129B1 (en) 2002-07-02
US6683171B1 (en) 2004-01-27
EP1105479A2 (de) 2001-06-13
JP2009039099A (ja) 2009-02-26
EP1105479B1 (de) 2011-01-12
US6884618B2 (en) 2005-04-26
US20080131411A1 (en) 2008-06-05
US7135612B2 (en) 2006-11-14
JP2012191949A (ja) 2012-10-11
US20050106601A1 (en) 2005-05-19
US20020168736A1 (en) 2002-11-14
US20050164247A1 (en) 2005-07-28
CA2339409A1 (en) 2000-02-24
WO2000009693A2 (en) 2000-02-24
DE69943129D1 (de) 2011-02-24

Similar Documents

Publication Publication Date Title
ATE495255T1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
NO20101157L (no) FAD4, FAD5, FAD5-2 og FAD6, nye fettsyredesaturase familiemedlemmer og anvendelser derav
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
BRPI0411182A (pt) método para aumentar a toleráncia de uma planta ao estresse abiótico, método para aumentar a biomassa de uma planta, construto de ácido nucléico, polipeptìdio isolado e célula de planta
DE60228477D1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
DE69829857D1 (de) Hypoxie-regulierte gene
EP1517144A3 (de) Verfahren zur Identifizierung eines Antikörpers, der einen humanen Vanilloid Rezeptor bindet und dessen Aktivität moduliert
DK0981631T3 (da) Polypeptider, som har aminopeptidase-aktivitet, og nukleinsyrer, som koder for samme
EP1546375A4 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
WO1999027098A3 (en) A-33 related antigens and their pharmacological uses
DK1364023T3 (da) Gener, de udtrykkes i höje niveauer i bruskvæv
DK0724637T4 (da) Kortikotropinfrigørende faktor2-receptorer
IL165007A0 (en) Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
NZ307444A (en) Polyphenol oxidase genes from lettuce and banana
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
DE69734828D1 (de) 5-aminolevulinsaure synthase aus aspergillus oryzae und dafuer kodierende nukleinsaeure
ATE161049T1 (de) Verfahren und nukleinsäuresequenzen zur expression des zellulose-synthase-operons
NO20025146L (no) Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav
BR0014926A (pt) Sistema de produção de proteìna
ATE382637T1 (de) Rezeptor-tyrosine-kinase gene
ATE298348T1 (de) Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung
DK0778347T3 (da) Protein med formodede helicase- og ATPase-egenskaber, som binder ATP og nukleinsyre

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties